Anavex Life Sciences (AVXL) vs enGene Therapeutics (ENGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
enGene Therapeutics (ENGN) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 80.5% versus a loss of 84.3%. Anavex Life Sciences is the larger company by market cap ($138.1 million vs $115.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | ENGN |
|---|---|---|
| Share price | $1.49 | $1.73 |
| Market cap | $138.12M | $115.94M |
| 1-day change | -3.25% | -2.81% |
| YTD return | -58.15% | -80.84% |
| 1-year return | -84.35% | -80.54% |
| 5-year return | -91.50% | — |
| EPS (TTM) | $-0.14 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.50 | $12.25 |
| 52-week low | $1.44 | $1.40 |
| Distance from 52-week high | -84.32% | -85.88% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +90.17% |
| Average volume | 983.35K | 748.14K |
| Shares outstanding | 92.70M | 67.02M |
| Employees | 34 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
AVXL vs ENGN FAQ
Which is bigger, Anavex Life Sciences or enGene Therapeutics?
Anavex Life Sciences (AVXL) is larger, with a market capitalization of $138.12M compared with $115.94M for enGene Therapeutics (ENGN).
Which stock has performed better over the past year, AVXL or ENGN?
ENGN returned -80.54% over the past 12 months, compared with -84.35% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and enGene Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.